NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$14.75

-0.58 (-3.78%)

(As of 09/27/2023 ET)

Compare

Today's Range: $14.70
▼
$15.72
50-Day Range: $15.25
▼
$23.88
52-Week Range: $14.70
▼
$39.85

Volume: 390,801 shs
Average Volume: 479,241 shs
Market Capitalization: $817.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.10

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 226.1% Upside
$48.10 Price Target
Short Interest: Bearish
13.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.55) to ($3.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

782nd out of 976 stocks

Biological Products, Except Diagnostic Industry

125th out of 159 stocks

4.3

Analyst's Opinion

Consensus Rating
Kymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.10, Kymera Therapeutics has a forecasted upside of 226.1% from its current price of $14.75.
Amount of Analyst Coverage
Kymera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
13.39% of the outstanding shares of Kymera Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Kymera Therapeutics has a short interest ratio ("days to cover") of 19.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Kymera Therapeutics has recently increased by 3.63%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Kymera Therapeutics does not currently pay a dividend.
Dividend Growth
Kymera Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KYMR.

2.7

News and Social Media Coverage

News Sentiment
Kymera Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Kymera Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kymera Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.67% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.55) to ($3.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kymera Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kymera Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kymera Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Price History

30 days | 90 days | 365 days | Advanced Chart

KYMR Stock News Headlines

September 18, 2023 | finance.yahoo.com

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

August 31, 2023 | finance.yahoo.com

Industry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19%

September 27, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 30, 2023 | msn.com

Morgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendation

August 29, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Kymera Therapeutics

August 28, 2023 | finance.yahoo.com

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

August 9, 2023 | msn.com

Kymera Therapeutics - Need More Developments Before Making This A Buy

August 8, 2023 | msn.com

Stifel Maintains Kymera Therapeutics (KYMR) Buy Recommendation

September 27, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

August 7, 2023 | markets.businessinsider.com

Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 6, 2023 | seekingalpha.com

Kymera Therapeutics: A Status Update

August 4, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendation

August 4, 2023 | markets.businessinsider.com

Expert Ratings for Kymera Therapeutics

August 3, 2023 | finance.yahoo.com

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

July 27, 2023 | finance.yahoo.com

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

July 9, 2023 | finance.yahoo.com

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

July 1, 2023 | msn.com

Truist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation

June 22, 2023 | seekingalpha.com

FDA grants orphan drug status to Kymera blood cancer drug KT-253

June 22, 2023 | finance.yahoo.com

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

June 21, 2023 | benzinga.com

Board Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Shares

June 16, 2023 | fool.com

Kymera Therapeutics (NASDAQ: KYMR)

June 15, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Kymera Therapeutics

June 15, 2023 | markets.businessinsider.com

Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus

June 14, 2023 | finance.yahoo.com

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

June 13, 2023 | msn.com

Kymera climbs on data updates for three drug programs

June 12, 2023 | seekingalpha.com

Kymera climbs on data updates for three drug programs (update)

See More Headlines

Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings: 8/03/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KYMR
CUSIP: N/A
CIK: 1815442
Web: www.kymeratx.com
Phone: 857-285-5300
Fax: N/A
Employees: 181
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.10
High Stock Price Forecast: $85.00
Low Stock Price Forecast: $31.00
Forecasted Upside/Downside: +226.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-154,810,000.00
Net Margins: -305.01%
Pretax Margin: -305.01%
Return on Equity: -33.17%
Return on Assets: -25.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.06
Quick Ratio: 7.06

Sales & Book Value

Annual Sales: $46.83 million
Price / Sales: 17.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.93 per share
Price / Book: 1.65

Miscellaneous

Outstanding Shares: 55,410,000
Free Float: 46,175,000
Market Cap: $817.30 million
Optionable: Not Optionable
Beta: 1.51

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Bruce L. Booth D.Phil. (Age 49)
DPHIL, Ph.D., Co-Founder & Chairman
Comp: $79.19k

Dr. Nello Mainolfi M.D. (Age 45)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $975.2k

Mr. Bruce N. Jacobs CFA
Chief Financial Officer

Dr. Jared A. Gollob M.D. (Age 58)
Chief Medical Officer
Comp: $637.81k

Dr. Jeremy G. Chadwick Ph.D. (Age 60)
Chief Operating Officer

Mr. Michael J. Todisco (Age 58)
VP of Accounting & Fin.

Mr. Vijay Sabesan (Age 51)
Sr. VP of Technical Operations

Ms. Justine E. Koenigsberg
VP of Investor Relations

Ms. Ellen V. Chiniara Esq. (Age 64)
J.D., Chief Legal Officer & Corp. Sec.

Ms. Melissa Brody
VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.
What is Kymera Therapeutics' stock price forecast for 2023?: 9 Wall Street research analysts have issued 1-year target prices for Kymera Therapeutics' stock. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's stock price to reach $48.10 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.
How have KYMR shares performed in 2023?: Kymera Therapeutics' stock was trading at $24.96 on January 1st, 2023. Since then, KYMR shares have decreased by 40.9% and is now trading at $14.75.
View the best growth stocks for 2023 here.
When is Kymera Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KYMR earnings forecast.
How were Kymera Therapeutics' earnings last quarter?: Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.03. The business had revenue of $16.51 million for the quarter, compared to analysts' expectations of $13.93 million. Kymera Therapeutics had a negative net margin of 305.01% and a negative trailing twelve-month return on equity of 33.17%. Kymera Therapeutics's revenue was up 43.4% on a year-over-year basis. During the same period last year, the firm earned ($0.78) earnings per share.
What ETFs hold Kymera Therapeutics' stock?: ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).
What other stocks do shareholders of Kymera Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?: (KYMR) raised $126 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.
What is Kymera Therapeutics' stock symbol?: Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."
Who are Kymera Therapeutics' major shareholders?: Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.82%), State Street Corp (4.73%), Rock Springs Capital Management LP (2.68%), Wasatch Advisors LP (2.16%), Dimensional Fund Advisors LP (1.52%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.
How do I buy shares of Kymera Therapeutics?: Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kymera Therapeutics' stock price today?: One share of KYMR stock can currently be purchased for approximately $14.75.
How much money does Kymera Therapeutics make?: Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $817.30 million and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.
How many employees does Kymera Therapeutics have?: The company employs 181 workers across the globe.
How can I contact Kymera Therapeutics?: Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial